Actinogen Medical Ltd (AU:ACW) — Market Cap & Net Worth
Market Cap & Net Worth: Actinogen Medical Ltd (ACW)
Actinogen Medical Ltd (AU:ACW) has a market capitalization of $130.32 Million (AU$184.18 Million) as of September 22, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18273 globally and #557 in its home market, demonstrating a -3.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Actinogen Medical Ltd's stock price AU$0.06 by its total outstanding shares 3178477638 (3.18 Billion). Also see ACW total assets for a full breakdown of the balance sheet.
Actinogen Medical Ltd Market Cap History: 2015 to 2026
Actinogen Medical Ltd's market capitalization history from 2015 to 2026. Data shows growth from $129.09 Million to $130.44 Million (0.40% CAGR). Also see how efficiently does Actinogen Medical Ltd generate cash for how efficiently the company converts equity into cash flow.
Actinogen Medical Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Actinogen Medical Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Actinogen Medical Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
24.99x
Actinogen Medical Ltd's market cap is 24.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $152.48 Million | $3.95 Million | -$3.63 Million | 38.57x | N/A |
| 2017 | $86.81 Million | $1.42 Million | -$3.19 Million | 61.33x | N/A |
| 2018 | $95.36 Million | $3.30 Million | -$6.23 Million | 28.89x | N/A |
| 2019 | $76.24 Million | $4.86 Million | -$9.89 Million | 15.68x | N/A |
| 2020 | $45.43 Million | $3.52 Million | -$5.33 Million | 12.92x | N/A |
| 2021 | $345.67 Million | $1.98 Million | -$3.92 Million | 174.22x | N/A |
| 2022 | $216.13 Million | $3.64 Million | -$9.50 Million | 59.37x | N/A |
| 2023 | $49.48 Million | $4.89 Million | -$10.75 Million | 10.12x | N/A |
| 2024 | $56.22 Million | $9.93 Million | -$13.04 Million | 5.66x | N/A |
| 2025 | $137.19 Million | $5.49 Million | -$14.73 Million | 24.99x | N/A |
Competitor Companies of ACW by Market Capitalization
Companies near Actinogen Medical Ltd in the global market cap rankings as of September 22, 2026. Review ACW goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Actinogen Medical Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $129.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #336 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $61.21 Billion USD ( AU$86.50 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #508 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.45 Billion | $510.72 |
| #336 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $798.17 |
| #455 | CSL Ltd | AU:CSL | $61.21 Billion | AU$178.30 |
| #508 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $172.94 |
Actinogen Medical Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Actinogen Medical Ltd's market cap moved from $129.09 Million to $ 130.44 Million, with a yearly change of 0.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$130.44 Million | -4.92% |
| 2025 | AU$137.19 Million | +144.00% |
| 2024 | AU$56.22 Million | +13.64% |
| 2023 | AU$49.48 Million | -77.11% |
| 2022 | AU$216.13 Million | -37.48% |
| 2021 | AU$345.67 Million | +660.89% |
| 2020 | AU$45.43 Million | -40.41% |
| 2019 | AU$76.24 Million | -20.05% |
| 2018 | AU$95.36 Million | +9.84% |
| 2017 | AU$86.81 Million | -43.07% |
| 2016 | AU$152.48 Million | +18.12% |
| 2015 | AU$129.09 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 22nd, 2026 the market cap of Actinogen Medical Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $130.32 Million USD |
| MoneyControl | $130.32 Million USD |
| MarketWatch | $130.32 Million USD |
| marketcap.company | $130.32 Million USD |
| Reuters | $130.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more